These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19122568)

  • 1. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
    Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
    Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
    Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFFICACY OF SILODOSIN (UROREC®) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: THE MAXIMUM DECREASE OF BLADDER OUTLET OBSTRUCTION INDEX.
    Khamzin A; Frolov R
    Georgian Med News; 2018 Mar; (276):18-23. PubMed ID: 29697376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
    Lee YS; Lee HN; Han JY; Choo MS; Lee KS
    J Urol; 2011 Mar; 185(3):1003-9. PubMed ID: 21251673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
    Lepor H; Hill LA
    Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign prostate hypertrophy, a proof of concept study in the spontaneously hypertensive rat supplemented with testosterone.
    Assaly R; Faugeroux J; Laurin M; Compagnie S; Alexandre L; Giuliano F; Behr-Roussel D
    BMC Urol; 2020 Aug; 20(1):132. PubMed ID: 32854676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
    Roehrborn CG; Cruz F; Fusco F
    Adv Ther; 2017 Jan; 33(12):2110-2121. PubMed ID: 27752927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.
    Tatemichi S; Akiyama K; Kobayashi M; Yamazaki Y; Yokoyama O; Uruno T
    J Urol; 2006 Sep; 176(3):1236-41. PubMed ID: 16890732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?
    Morgia G
    Eur Urol; 2011 Mar; 59(3):353-5; discussion 355. PubMed ID: 21130562
    [No Abstract]   [Full Text] [Related]  

  • 18. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Hirakawa A; Gotoh M
    Urology; 2016 Feb; 88():149-54. PubMed ID: 26592467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
    Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
    PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.